High-dose hemodiafiltration benefits patients with kidney failure than standard hemodialysis

According to a recent study, patients with kidney failure were known to benefit from high-dose hemodiafiltration as compared with standard hemodialysis. This study’s results were published in The New England Journal of Medicine.

This study was a multinational, pragmatic, randomized, controlled trial that included 1360 patients with kidney failure who had received high-flux hemodialysis for a period of at least 3 months. Out of these, 683 were assigned to high dose hemodiafiltration and 677 continued on high flux hemodialysis[SB1] . All the patients were deemed to be candidates for a convection volume of at least 23 liters per session [SB2] . The primary outcome measured was death due to any cause. The time for median follow-up was 30 months.

It was observed that the mean convection volume in the hemodiafiltration group was found to be 25.3 liters/session. While death due to any cause was 118 patients in the hemodiafiltration group, it was seen in 148 patients in the hemodialysis group.

Hence, it may be concluded that in patients with kidney failure resulting in kidney-replacement therapy, high-dose hemodiafiltration was found to lower risk of death due to any cause than conventional high-flux hemodialysis and therefore, may be a better option for use.